This product's status changed to Expired on 2023.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Summary
- Main use
- Treatment of chronic noninfectious uveitis of the posterior segment of the eye
- Who uses it
- Adults
- Adult dosage
- This drug is implanted in the posterior segment of the inflamed eye through an incision in the pars plana. The implant contains a 0.59mg fluocinolone acetonide tablet. This drug initially releases fluocinolone acetonide at a rate of 0.6μg/day, with the release rate decreasing to a steady state from the first month and designed to release at a rate of 0.3-0.4μg/day for approximately 30 months. Thereafter, if uveitis recurs due to depletion of fluocinolone acetonide from this drug, this drug may be replaced.
Ingredients
- Importer
- Bausch Health Korea
Efficacy & effects
Treatment of chronic noninfectious uveitis of the posterior segment of the eye
- Chronic non-infectious uveitis of the posterior segment of the eye
View approved original textHide original text
This medication is used to treat chronic non-infectious uveitis occurring in the posterior segment of the eye. This condition can cause vision loss or pain due to inflammation within the eye, and the medication helps to reduce inflammation, aiding in the restoration of eye health. Thus, it effectively manages internal eye inflammation, contributing to vision protection and symptom improvement.
Dosage and Administration
Adult dosage
This drug is implanted in the posterior segment of the inflamed eye through an incision in the pars plana. The implant contains a 0.59mg fluocinolone acetonide tablet. This drug initially releases fluocinolone acetonide at a rate of 0.6μg/day, with the release rate decreasing to a steady state from the first month and designed to release at a rate of 0.3-0.4μg/day for approximately 30 months. Thereafter, if uveitis recurs due to depletion of fluocinolone acetonide from this drug, this drug may be replaced.
Precautions
This medication should not be used in patients with viral keratitis or conjunctivitis, particularly herpes simplex keratitis, smallpox, or varicella (chickenpox). Additionally, patients with mycobacterial infections or fungal diseases in the eye should not use this medication. It should not be administered in cases of known or suspected allergic reactions to this medication or other corticosteroids. Surgical implantation of this medication into the eye carries various risks of complications including cataracts, retinal detachment, vision loss, intraocular inflammation, changes in intraocular pressure, retinal detachment, and vitreous hemorrhage. Vision may temporarily decrease for about 1 to 4 weeks post-surgery, which is a normal occurrence during the surgical process. Continued use of corticosteroids may lead to glaucoma, optic nerve damage, decreased vision and visual field, and posterior cataract formation; therefore, intraocular pressure should be monitored regularly. Within approximately 34 weeks post-implantation, many patients may require medication to lower intraocular pressure, and some patients may need filtration surgery within an average of 2 years. The use of corticosteroids can exacerbate eye viral infections, so particular caution is warranted for patients with a history of herpes simplex. Corticosteroids can also suppress immune responses, increasing the risk of eye infections, so use should be avoided during acute symptoms of eye infections. The administration of this medication post-cataract surgery may delay recovery and increase blister formation. While using this medication, various adverse reactions may occur, including glaucoma, cataracts, increased intraocular pressure, eye pain, surgery-related complications, infections, thus, regular ophthalmic check-ups are necessary. During surgery, the sterile condition of this medication must be strictly maintained, and care should be taken not to damage the implant. This medication is not re-sterilized. It is advisable to avoid simultaneous surgery on both eyes as it may increase the risk of infection. While this medication treats eye inflammation, it is not used for potential treatment of other diseases, so additional medications may be used as directed by a physician. If movement of the implant occurs within the eye, corneal damage or visual disturbances may arise, therefore if any abnormal symptoms occur, immediate assessment is necessary. During pregnancy, the use should be limited to situations where the potential benefits outweigh the risks to the fetus, and in nursing mothers, caution should be exercised due to possible transmission of the medication through breast milk. It is advisable not to use this medication in children under 12 years of age, as safety and efficacy have not been established. This medication should be stored out of reach of children, in a tightly sealed container protected from direct sunlight, and in a cool place to prevent freezing.
Side effects
Cataract formation, chorioretinal detachment, temporary vision impairment, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, loss of vitreous, wound rupture, vision impairment, optic nerve damage, decrease in vision and field of vision, posterior subcapsular cataract formation, delayed wound healing, perforation of the eye in areas with thin sclera, secondary eye infections, corneal ulcers, eye pain, postoperative lens fragments, graft dislocation, injury, mechanical complications of the graft, corneal edema, postoperative complications, complications of the wound after surgery, wound rupture, visual acuity reduction, conjunctival hemorrhage, conjunctival hyperemia, glaucoma, blurred vision, eye sensory abnormalities, eye irritation, pruritus, vitreous floaters, macular degeneration, vitreous hemorrhage, ectropion, ocular inflammation, eyelid edema, increased tear secretion, dry eye, macular edema, visual disturbances, eye discharge, conjunctival edema, glare, blepharitis, corneal edema, photopsia, retinal hemorrhage, vitreous opacities, ocular swelling, headache, nasopharyngitis, arthralgia, sinusitis, dizziness, fever, nausea, cough, influenza, upper respiratory tract infection, vomiting, limb pain, low back pain, rash, pain
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container that prevents light exposure, ideally at a cool room temperature between 15 to 25 degrees Celsius.
Appearance and packaging
Appearance
This medication is contained in a silicone elastomer cup with a sealing tab, inside a polycarbonate plastic case (case base and case cup) sealed with aluminum foil in a Tyvek? package.
Package unit
1 unit
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.